ID,Sentence,Sentence_clean,sentiment
1,The results in 2nd line treatment show an ORR of 33% with some patients having durable responses resulting in an apparent PFS plateau,results nd line treatment show orr  patients durable responses resulting apparent pfs plateau,Positive
2,The long duration of response and high durable response rate observed after 6-month minimum follow-up is further substantiated by the 12-months minimum follow-up analysis,long duration response high durable response rate observed month minimum followup substantiated months minimum followup analysis,Positive
4,"Therefore, the clinical benefit in 2nd line treatment is considered clinically meaningful and the magnitude of the effect is significant compared to chemotherapy",therefore clinical benefit nd line treatment considered clinically meaningful magnitude effect significant compared chemotherapy,Positive
5,"The data provided in 1st line, although preliminary, showed activity of avelumab in mMCC in terms of response rate, and evidence of a similar durable response from the small subset of patients with a longer follow-up compared to 2nd line treatment",data provided st line although preliminary showed activity avelumab mmcc terms response rate evidence similar durable response small subset patients longer followup compared nd line treatment,Positive
6,"Taking into account the intrinsic limitation of single arm studies, the rarity of the disease and the challenges to compare the results with data from historical controls and in the literature, the currently available data are deemed to support the efficacy of avelumab in both pre-treated and chemotherapy-naïve patients",taking account intrinsic limitation single arm studies rarity disease challenges compare results data historical controls literature currently available data deemed support efficacy avelumab pretreated chemotherapynave patients,Positive
15,The safety data collected at an earlier data cut remains consistent with longer follow up ,safety data collected earlier data cut remains consistent longer follow,Positive
16,No major concerns have been identified in the updated analysis,major concerns identified updated analysis,Positive
17,The safety of avelumab in the proposed indication appears to be acceptable and manageable with the recommendations as proposed in the SmPC and the RMP,safety avelumab proposed indication appears acceptable manageable recommendations proposed smpc rmp,Positive
21,Biosimilarity of CT-P10 and MabThera is considered demonstrated based on the efficacy data.,biosimilarity ctp mabthera considered demonstrated based efficacy data,Positive
22,"In the pivotal RA trial, efficacy results in terms of DAS28 and ACR were shown to be comparable between CT-P10 and MabThera.",pivotal ra trial efficacy results terms das acr shown comparable ctp mabthera,Positive
23,"In addition, PK data discussed support the extrapolation to the autoimmune indications MPA/GPA.",addition pk data discussed support extrapolation autoimmune indications mpagpa,Positive
24,"The objectives of study CT-P10 3.3 were to demonstrate similarity in pharmacokinetics and non-inferiority in efficacy of CT-P10 to Rituxan as primary endpoints when coadministered with CVP in patients with advanced FL; these objectives have been met and furthermore, extrapolation in the context of NHL and CLL indications is acceptable.",objectives study ctp  demonstrate similarity pharmacokinetics noninferiority efficacy ctp rituxan primary endpoints coadministered cvp patients advanced fl objectives met furthermore extrapolation context nhl cll indications acceptable,Positive
26,"Therefore, the available safety data are considered supportive of biosimilarity between CT-P10 and MabThera.",therefore available safety data considered supportive biosimilarity ctp mabthera,Positive
28,The frequencies and nature of the adverse events were in line with those reported for the innovator MabThera/Rituxan in the RA and NLH study populations.,frequencies nature adverse events line reported innovator mabtherarituxan ra nlh study populations,Positive
32,A summary of the literature with regard to clinical data of Daptomycin Hospira and justifications that the product is essentially similar in properties with regards to safety and efficacy of the reference product was provided and was accepted by the CHMP.,summary literature regard clinical data daptomycin hospira justifications product essentially similar properties regards safety efficacy reference product provided accepted chmp,Positive
33,This is in accordance with the relevant guideline and additional clinical studies were not considered necessary.,accordance relevant guideline additional clinical studies considered necessary,Positive
34,The superiority to placebo was demonstrated for both dupilumab doses as monotherapy or in combination with TCS in AD patients who are insufficiently controlled with topical therapies alone.,superiority placebo demonstrated dupilumab doses monotherapy combination tcs ad patients insufficiently controlled topical therapies alone,Positive
37,"Based on the presented and available data, dupilumab has been found to have an acceptable safety profile.",based presented available data dupilumab found acceptable safety profile,Positive
45,Furthermore according to the meta-analysis of the four pivotal studies performed in patients meeting the ESSIC classification 2X to 3C the pooled response rate under PPS treatment was 2-fold higher than the pooled response rate under placebo (“GRA” primary endpoint and also pain and urgency)and efficacy of PPS was considered sufficiently demonstrated in this population,furthermore according metaanalysis four pivotal studies performed patients meeting essic classification x c pooled response rate pps treatment fold higher pooled response rate placebo gra primary endpoint pain urgencyand efficacy pps considered sufficiently demonstrated population,Positive
46,"Overall, the safety profile of PPS is not considered of concern.",overall safety profile pps considered concern,Positive
48,This risk is adequately addressed in various sections of the SmPC and as important identified risk in the RMP.,risk adequately addressed various sections smpc important identified risk rmp,Positive
49,Based on the presented bioequivalence study the test formulation Emtricitabine/Tenofovir disoproxil Krka d.d. 200mg/245mg film coated tablets of Krka d.d. Slovenia is considered bioequivalent with the reference Truvada 200mg/245mg film coated tablets manufactured by Gilead Sciences Intl. Ltd. Ireland MA holder: Gilead Sciences UK.,based presented bioequivalence study test formulation emtricitabinetenofovir disoproxil krka dd mgmg film coated tablets krka dd slovenia considered bioequivalent reference truvada mgmg film coated tablets manufactured gilead sciences intl ltd ireland ma holder gilead sciences uk,Positive
50,The application contains an adequate review of published clinical data and the bioequivalence has been shown between Granpidam and Viagra® 100 mg film-coated tablets.,application contains adequate review published clinical data bioequivalence shown granpidam viagra  mg filmcoated tablets,Positive
51,A biowaiver for the 20 mg strength is considered acceptable.,biowaiver  mg strength considered acceptable,Positive
52,Based on the presented bioequivalence study Granpidam is considered bioequivalent with Viagra (reference product used).,based presented bioequivalence study granpidam considered bioequivalent viagra reference product used,Positive
53,"The results of study 084-09 with 100mg formulation can be extrapolated to other strengths 20mg, according to conditions in the Guidelines.",results study  mg formulation extrapolated strengths mg according conditions guidelines,Positive
54,The results presented on efficacy support the biosimilarity claim between the test product SB5 and the reference product EU Humira.,results presented efficacy support biosimilarity claim test product sb reference product eu humira,Positive
55,The number of subjects is sufficient for comparing the safety profile of the biosimilar candidate SB5 and reference medicinal product EU-Humira and studying the safety of a biosimilar product for up to one year.,number subjects sufficient comparing safety profile biosimilar candidate sb reference medicinal product euhumira studying safety biosimilar product one year,Positive
56,"Broadly, the number, severity and type of TEAEs, SAEs, AEs of special interest, treatment discontinuations due to AEs, laboratory findings were comparable between SB5 and Humira and mirroring the safety profile as described in the SmPC of Humira.",broadly number severity type teaes saes aes special interest treatment discontinuations due aes laboratory findings comparable sb humira mirroring safety profile described smpc humira,Positive
57,"The frequency of related AEs, severity of AEs and AESIs remained similar for the group who transitioned from Humira to SB5 at week 24.",frequency related aes severity aes aesis remained similar group transitioned humira sb week ,Positive
59,The submitted additional analyses further support the comparability of the safety profile of SB5 and Humira.,submitted additional analyses support comparability safety profile sb humira,Positive
60,"With regard to immunogenicity, the incidence and titre distribution of ADAs were compared and seemed similar for SB5 and Humira, with about half of all subjects developing neutralising antibodies in each treatment group.",regard immunogenicity incidence titre distribution adas compared seemed similar sb humira half subjects developing neutralising antibodies treatment group,Positive
61,No worsening of the immunogenicity profile was observed after transitioning from Humira to SB5.,worsening immunogenicity profile observed transitioning humira sb,Positive
63,"In light of established biosimilarity on quality level, the remaining uncertainty that the safety profile of Inhixa and Clexane differs significantly was considered low enough to conclude on similarity.",light established biosimilarity quality level remaining uncertainty safety profile inhixa clexane differs significantly considered low enough conclude similarity,Positive
66,This data is considered supportive in establishing biosimilarity.,data considered supportive establishing biosimilarity,Positive
67,"Both studies, demonstrated that SAR342434 is non-inferior to Humalog in improvement of glycaemic control by Week 26 and therefore provided strong supportive evidence about the comparability/ biosimilarity of the two products.",studies demonstrated sar noninferior humalog improvement glycaemic control week  provided strong supportive evidence comparability biosimilarity two products,Positive
68,The 12-month results of study EFC12619 further supported similar clinical efficacy of SAR342434 and Humalog in T1DM subjects.,month results study efc supported similar clinical efficacy sar humalog tdm subjects,Positive
69,The size of the safety database and duration of exposure is considered appropriate for the evaluation of the general safety profile of Insulin lispro Sanofi.,size safety database duration exposure considered appropriate evaluation general safety profile insulin lispro sanofi,Positive
70,Safety and tolerability of Insulin lispro Sanofi and Humalog seem to be comparable and thus support biosimilarity of these two products.,safety tolerability insulin lispro sanofi humalog seem comparable thus support biosimilarity two products,Positive
72,Treatment-emergent AIA did not affect efficacy or safety endpoints in either T1DM or T2DM subjects.,treatmentemergent aia affect efficacy safety endpoints either tdm tdm subjects,Positive
73,"In conclusion, the safety profile of Insulin lispro Sanofi is acceptable and not different to that of Humalog.",conclusion safety profile insulin lispro sanofi acceptable different humalog,Positive
74,"The bioequivalence of the applied product Ivabradine, film-coated tablets, 7.5 mg with the respective strength of the reference product Procoralan film-coated tablets of Les Laboratoires Servier has been demonstrated in one bioequivalence study (study 14-VIN-785).",bioequivalence applied product ivabradine filmcoated tablets  mg respective strength reference product procoralan filmcoated tablets les laboratoires servier demonstrated one bioequivalence study study vin,Positive
75,"The study has been performed under fed conditions, which reflects recommendations in the brand leader’s SPC for the administration of the product.",study performed fed conditions reflects recommendations brand leaders spc administration product,Positive
76,The sample size was calculated to provide adequate power of bioequivalence analysis.,sample size calculated provide adequate power bioequivalence analysis,Positive
77,The statistical methodology used in the studies is justified and consistent with the principles of guidelines on the investigation of bioequivalence.,statistical methodology used studies justified consistent principles guidelines investigation bioequivalence,Positive
78,In accordance with the study protocol the study meets the bioequivalence criteria as 90% confidence intervals for the ln-transformed pharmacokinetic parameters Cmax and AUC0-t for ivabradine is within the acceptance range of 80.00% - 125.00% with power (1-β) 99.45 and 99.99 respectively.,accordance study protocol study meets bioequivalence criteria  confidence intervals lntransformed pharmacokinetic parameters cmax auct ivabradine within acceptance range   power    respectively,Positive
79,The bioequivalence study appears to have been well conducted.,bioequivalence study appears well conducted,Positive
80,"An acceptable justification for a biowaiver of Ivabradine Hydrochloride, 5 mg, film-coated tablets has been provided.",acceptable justification biowaiver ivabradine hydrochloride  mg filmcoated tablets provided,Positive
81,"to the EMA Guideline on the Investigation of Bioequivalence (CPMP/EWP/QWP/1401/98 Rev. 1/ Corr **), Ivabradine 5 mg film-coated tablets satisfy the conditions for waiver of bioequivalence studies conducted on the applied product 7.5 mg strength.",ema guideline investigation bioequivalence cpmpewpqwp rev  corr ivabradine  mg filmcoated tablets satisfy conditions waiver bioequivalence studies conducted applied product  mg strength,Positive
82,"The efficacy data of the two phase 3 placebo-controlled studies in patients who received background DMARDs showed that both dose regimens of sarilumab (150 mg q2w, 200 mg q2w) were superior to placebo regarding improvement of signs and symptoms (ACR20 responses), of physical function (change from baseline in HAQ-DI) and of progression in structural damage (mTSS, only study EFC11072).",efficacy data two phase  placebocontrolled studies patients received background dmards showed dose regimens sarilumab  mg qw  mg qw superior placebo regarding improvement signs symptoms acr responses physical function change baseline haqdi progression structural damage mtss study efc,Positive
83,The active-comparator study demonstrated the efficacy of sarilumab as monotherapy and relative to the biologic DMARD adalimumab.,activecomparator study demonstrated efficacy sarilumab monotherapy relative biologic dmard adalimumab,Positive
84,"Overall, data of the submitted studies are considered overall adequate to identify the patient population of the indication.",overall data submitted studies considered overall adequate identify patient population indication,Positive
87,No new safety concerns were identified during the development program in the clinical trial population.,new safety concerns identified development program clinical trial population,Positive
88,The efficacy of the combination of lenvatinib with everolimus has been shown.,efficacy combination lenvatinib everolimus shown,Positive
89,Lenvatinib/everolimus combination therapy demonstrated improved PFS compared to everolimus monotherapy with a median PFS of 14.6 months vs. 5.5 months.,lenvatinibeverolimus combination therapy demonstrated improved pfs compared everolimus monotherapy median pfs  months vs  months,Positive
90,Additional sensitivity analyses performed confirmed the robustness of observed PFS.,additional sensitivity analyses performed confirmed robustness observed pfs,Positive
91,"Furthermore, encouraging signs of a prolonged OS were seen in patients treated with the combination of lenvatinib and everolimus combination therapy as per the primary analysis as well as the two updated analyses that span a more than 1-year period.",furthermore encouraging signs prolonged os seen patients treated combination lenvatinib everolimus combination therapy per primary analysis well two updated analyses span year period,Positive
92,A similar trend towards prolonged OS was also observed in favour of lenvatinib monotherapy but less obvious than with combination therapy.,similar trend towards prolonged os observed favour lenvatinib monotherapy less obvious combination therapy,Positive
93,The overall safety profile of lenvatinib-everolimus combination is consistent with known safety profiles of its components observed either in other indications (for lenvatinib) or in the intended indication (for everolimus).,overall safety profile lenvatinibeverolimus combination consistent known safety profiles components observed either indications for lenvatinib intended indication for everolimus,Positive
94,The reported toxicity was in general predictable and manageable.,reported toxicity general predictable manageable,Positive
95,No new safety signal has been reported.,new safety signal reported,Positive
96,"However, most of these adverse events were well managed by dose reduction, interruption or by additional medical treatment.",however adverse events well managed dose reduction interruption additional medical treatment,Positive
106,"Based on the available data, the CHMP considered that all criteria for a BCS-based biowaiver were met. ",based available data chmp considered criteria bcsbased biowaiver met,Positive
107,"Therefore the absence of a bioequivalence study was considered justified and the CHMP concluded that no clinical data were needed to support the application for Lacosamide Accord 50 mg, 100 mg, 150 mg and 200 mg film-coated tablets as a generic medicinal product to Vimpat.",absence bioequivalence study considered justified chmp concluded clinical data needed support application lacosamide accord  mg  mg  mg  mg filmcoated tablets generic medicinal product vimpat,Positive
108,"Overall, the available clinical efficacy data were considered adequate to support the use of cladribine in the treatment of adult patients with highly active RMS as defined by clinical or imaging features.",overall available clinical efficacy data considered adequate support use cladribine treatment adult patients highly active rms defined clinical imaging features,Positive
109,Results from the pivotal study CLARITY showed a clinically relevant effect of cladribine in patients with RMS in terms of reduction of relapse rate as well as MRI lesions and delay in disability progression.,results pivotal study clarity showed clinically relevant effect cladribine patients rms terms reduction relapse rate well mri lesions delay disability progression,Positive
111,"Furthermore, data in SPMS patients with superimposed relapses, although very limited, supported a beneficial effect of cladribine on the relapse rate in this population.",furthermore data spms patients superimposed relapses although limited supported beneficial effect cladribine relapse rate population,Positive
113,The data furthermore support the use of a cumulative dose of 3.5 mg/kg to be administered in 2 courses each for 2 years.,data furthermore support use cumulative dose  mgkg administered  courses  years,Positive
114,Maintenance of the treatment effect in year 3 and 4 was supported by long-term data from CLARITY EXT.,maintenance treatment effect year   supported longterm data clarity ext,Positive
116,"Overall, the CHMP was of the view that the available clinical safety data were adequate for the purpose of assessing the safety of cladribine for the use as treatment of adult patients with highly active RMS.",overall chmp view available clinical safety data adequate purpose assessing safety cladribine use treatment adult patients highly active rms,Positive
119,"Overall, the risk minimisation measures including the safety information in the product information as well as the prescriber and patient guide were considered adequate to address the risks with cladribine treatment, while further data are gathered in the post-marketing setting",overall risk minimisation measures including safety information product information well prescriber patient guide considered adequate address risks cladribine treatment data gathered postmarketing setting,Positive
121,In the HCV GT1-infected population (the most widely represented in the EU) the observed results -with 99% SVR12 achieved with a convenient 8 weeks treatment duration in non-cirrhotic TN or TE-PRS patients and 97% in cirrhotic patients with a 12 weeks treatment duration- support the fact that this FDC will represent an optimization in the therapeutic armamentarium. ,hcv gtinfected population the widely represented eu observed results with  svr achieved convenient  weeks treatment duration noncirrhotic tn teprs patients  cirrhotic patients  weeks treatment duration support fact fdc will represent optimization therapeutic armamentarium,Positive
123,"CHMP thus acknowledged that the applicant’s proposal for a treatment recommendation could overall be followed in DAA treatment naïve patients, having in mind the possibility of bridging efficacy from GT1 based on comparable in vitro activity leading to favour a simplified regimen for a programmatic approach to HCV eradication (targeted by 2030 by WHO).",chmp thus acknowledged applicants proposal treatment recommendation overall followed daa treatment nave patients mind possibility bridging efficacy gt based comparable vitro activity leading favour simplified regimen programmatic approach hcv eradication targeted  who,Positive
125,The safety profile of Maviret (glecaprevir/pibrentasvir) is favourable with no major concern identified.,safety profile maviret glecaprevirpibrentasvir favourable major concern identified,Positive
127,This has been appropriately covered in the Maviret SmPC by the addition of a contra-indication with EE-containing medicines.,appropriately covered maviret smpc addition contraindication eecontaining medicines,Positive
130,The concerns raised during the procedure regarding the BE have been satisfactorily answered and the product is approvable from the clinical point of view.,concerns raised procedure regarding satisfactorily answered product approvable clinical point view,Positive
133,The CHMP considered this application acceptable from clinical point of view.,chmp considered application acceptable clinical point view,Positive
134,A summary of the literature with regard to clinical data of Pemetrexed Hospira UK Limited and justifications that the different salt of the active substance does not differ significantly in properties with regards to safety and efficacy of the reference product was provided and was accepted by the CHMP. ,summary literature regard clinical data pemetrexed hospira uk limited justifications different salt active substance differ significantly properties regards safety efficacy reference product provided accepted chmp,Positive
136,A single dose bioequivalence study was considered sufficient since the application concerns an immediate release formulation.,single dose bioequivalence study considered sufficient application concerns immediate release formulation,Positive
167,"Since Rolufta application is an informed consent of Incruse application, the clinical data in support of the Rolufta application are identical to the up-to-date clinical data of Incruse dossier, which have been assessed and authorised (including all post-marketing procedures).",rolufta application informed consent incruse application clinical data support rolufta application identical uptodate clinical data incruse dossier assessed authorised including postmarketing procedures,Positive
168,"Overall, ABP 501 has in the RA study shown similarity to adalimumab in several analyses.",overall abp  ra study shown similarity adalimumab several analyses,Positive
169,"The primary endpoint was met, and similarity at week 24 was indicated with low point estimates and narrow CI intervals both for ACR20 RR and Risk Difference.",primary endpoint met similarity week  indicated low point estimates narrow ci intervals acr rr risk difference,Positive
170,Also mean change in DAS28-CRP showed high similarity at all visits.,mean change dascrp showed high similarity visits,Positive
172,"However, these results are not seen for DAS28 which is favourable, or for ACR50 or ACR70, and as such it is concluded, that the difference seen at week 2 in ACR20 is likely to be a chance finding rather than a true difference.",however results seen das favourable acr acr concluded difference seen week  acr likely chance finding rather true difference,Positive
173,"Also the psoriasis study met the primary endpoint with a point estimate of difference of 2% with narrow CIs, indicating similarity.",psoriasis study met primary endpoint point estimate difference  narrow cis indicating similarity,Positive
175,"Overall, clinical similarity between ABP 501 and adalimumab has been demonstrated.",overall clinical similarity abp  adalimumab demonstrated,Positive
176,The safety profile of ABP 501 and Humira is considered comparable.,safety profile abp  humira considered comparable,Positive
177,"The majority of treated infants with infantile-onset SMA achieved improvement, with a great proportion reaching a clinically meaningful and continued improvements in motor milestones (e.g. independent sitting, standing and walking), muscle strength, and motor function that exceed those of the sham control-treated infants in Study CS3B and the natural history of the disease, where a progressive loss of motor function is observed",majority treated infants infantileonset sma achieved improvement great proportion reaching clinically meaningful continued improvements motor milestones eg independent sitting standing walking muscle strength motor function exceed sham controltreated infants study csb natural history disease progressive loss motor function observed,Positive
178,Data from treated pre-symptomatic infants with genetically confirmed SMA show that they are achieving motor milestones and developing muscle strength and motor function with the nusinersen treatment that are more consistent with those of normal infants than symptomatic infants with SMA,data treated presymptomatic infants genetically confirmed sma show achieving motor milestones developing muscle strength motor function nusinersen treatment consistent normal infants symptomatic infants sma,Positive
179,Subjects with later-onset SMA who received nusinersen achieved and maintained motor function across multiple measures and milestones such as the ability to walk that are completely inconsistent with natural history,subjects lateronset sma received nusinersen achieved maintained motor function across multiple measures milestones ability walk completely inconsistent natural history,Positive
181,Data from the ongoing studies in infantile-onset SMA support that treatment with nusinersen has the potential to prolong overall and event-free survival,data ongoing studies infantileonset sma support treatment nusinersen potential prolong overall eventfree survival,Positive
182,"They also support the need for early treatment with nusinersen, since shortly after the loading phase was complete, the rate of ventilation among nusinersen-treated subjects separated from that of the controls",support need early treatment nusinersen shortly loading phase complete rate ventilation among nusinersentreated subjects separated controls,Positive
183,"Taken together, these data demonstrate consistently that nusinersen has produced meaningful benefits across a broad range of SMA phenotypes",taken together data demonstrate consistently nusinersen produced meaningful benefits across broad range sma phenotypes,Positive
184,"The consistency among the various key clinically meaningful endpoints, each of which provide independent measures central to the pathology of SMA, support significant efficacy in both pre-symptomatic and symptomatic subjects and across infantile-onset and later-onset SMA",consistency among various key clinically meaningful endpoints provide independent measures central pathology sma support significant efficacy presymptomatic symptomatic subjects across infantileonset lateronset sma,Positive
198,Review of the available data demonstrated no safety concerns due to nusinersen exposure,review available data demonstrated safety concerns due nusinersen exposure,Positive
199,The majority of AEs and SAEs reported in subjects exposed to nusinersen were consistent with the nature and frequency of events typically occurring in the context of SMA,majority aes saes reported subjects exposed nusinersen consistent nature frequency events typically occurring context sma,Positive
201,"In addition, the fatality rate in nusinersen-treated subjects with infantile-onset SMA was about half that of sham-controlled subjects",addition fatality rate nusinersentreated subjects infantileonset sma half shamcontrolled subjects,Positive
202,"nusinersen has demonstrated a favourable safety and efficacy pattern in the treatment of infantile-onset SMA from a randomized controlled clinical study, Study CS3B",nusinersen demonstrated favourable safety efficacy pattern treatment infantileonset sma randomized controlled clinical study study csb,Positive
203,"This was supported by favourable safety and efficacy data from the interim analysis of a randomized controlled clinical study, CS4 in later-onset subjects, open-label studies in pre-symptomatic subjects, and subjects with infantile-onset and later-onset SMA, where the attainment of motor milestones in subjects receiving treatment differed from that seen in the natural history of SMA",supported favourable safety efficacy data interim analysis randomized controlled clinical study cs lateronset subjects openlabel studies presymptomatic subjects subjects infantileonset lateronset sma attainment motor milestones subjects receiving treatment differed seen natural history sma,Positive
204,"Based on the totality of the data, it can be agreed that nusinersen has a positive benefit/risk profile for treating SMA",based totality data agreed nusinersen positive benefitrisk profile treating sma,Positive
206,The FRC has been investigated in a clinical programme of adequate design.,frc investigated clinical programme adequate design,Positive
208,Study EFC12404 provides relevant information on the contribution of the mono-components to the effect of the FRC.,study efc provides relevant information contribution monocomponents effect frc,Positive
211,"With the FRC, the decrease in HbA1c was achieved without increase in body weight, and without an increase in the reporting of hypoglycaemia compared to patients on monotherapy with insulin glargine.",frc decrease hbac achieved without increase body weight without increase reporting hypoglycaemia compared patients monotherapy insulin glargine,Positive
218,"However, further analyses have shown that only a small proportion of patients (7% and 15%, study EFC12404 and EFC12405 respectively) had both reached the maximum dose and were in need of intensified treatment at week 30",however analyses shown small proportion patients   study efc efc respectively reached maximum dose need intensified treatment week ,Positive
219,"In addition, data from the lixisenatide file has been presented which shows maintenance of efficacy up to 76 weeks in combination with basal insulin.",addition data lixisenatide file presented shows maintenance efficacy  weeks combination basal insulin,Positive
220,Thus it appears plausible that the effect can be maintained for a majority of patients at the doses,thus appears plausible effect maintained majority patients doses,Positive
221,No new or unexpected adverse reactions were noted with the fixed combination of lixisenatide/insulin glargine (FRC) compared to the mono-components.,new unexpected adverse reactions noted fixed combination lixisenatideinsulin glargine frc compared monocomponents,Positive
223,The incidences of documented hypoglycaemic episode were comparable between the FRC and insulin glargine group.,incidences documented hypoglycaemic episode comparable frc insulin glargine group,Positive
225,Immunological reactions such as allergic reactions and injections site reactions were few and equally distributed between the different treatment groups.,immunological reactions allergic reactions injections site reactions equally distributed different treatment groups,Positive
226,A lower frequency of patients developed lixisenatide antibodies (ADA) in the FRC group (36%) compared to the lixisenatide group (48%).,lower frequency patients developed lixisenatide antibodies ada frc group  compared lixisenatide group ,Positive
227,The RMP adequately reflects the safety concerns listed for the two monocomponents. The,rmp adequately reflects safety concerns listed two monocomponents,Positive
228,"Overall, the fixed combination of lixisenatide/insulin glargine demonstrates a comparable safety profile as the two mono-components.",overall fixed combination lixisenatideinsulin glargine demonstrates comparable safety profile two monocomponents,Positive
229,There are no major objections based on the efficacy data.,major objections based efficacy data,Positive
231,Bioequivalence of the FDC to the separate components has been established.,bioequivalence fdc separate components established,Positive
233,Preliminary results from the ongoing phase 3 studies are reassuring in this respect.,preliminary results ongoing phase  studies reassuring respect,Positive
234,The safety profile of the D/C/F/TAF FDC is largely based on the well-established safety profile of the individual components.,safety profile dcftaf fdc largely based wellestablished safety profile individual components,Positive
235,The safety profile of D/C/F/TAF FDC is supported by the results from the phase 2 study and as well by the preliminary results from the ongoing phase 3 studies.,safety profile dcftaf fdc supported results phase  study well preliminary results ongoing phase  studies,Positive
236,The observed safety profile is in line with expectations and did not raise additional concerns.,observed safety profile line expectations raise additional concerns,Positive
237,"Since Tadalafil Lilly application is an informed consent of Cialis application, the clinical data in support of the Tadalafil Lilly application are identical to the up-to-date clinical data of Cialis dossier, which have been assessed and authorised (including all post-marketing procedures).",tadalafil lilly application informed consent cialis application clinical data support tadalafil lilly application identical uptodate clinical data cialis dossier assessed authorised including postmarketing procedures,Positive
238,A summary of the literature with regard to clinical data of tadalafil and two bioequivalence studies were provided to demonstrate that the active substance does not differ significantly in properties with regards to safety and efficacy of the reference product and was accepted by the CHMP.,summary literature regard clinical data tadalafil two bioequivalence studies provided demonstrate active substance differ significantly properties regards safety efficacy reference product accepted chmp,Positive
239,"Study TRIPLE 5, triple therapy with BDP/FF/GB (CHF 5993) had a statistically significant and clinically relevant superior effect on pre-dose and 2-h post-dose FEV1 at week 26 than BDP/FF (Foster).",study triple  triple therapy bdpffgb chf  statistically significant clinically relevant superior effect predose h postdose fev week  bdpff foster,Positive
241,"Nevertheless, the responder analysis indicates a benefit for CHF 5993 compared with Foster on TDI symptoms for a greater proportion of patients.",nevertheless responder analysis indicates benefit chf  compared foster tdi symptoms greater proportion patients,Positive
242,"Also, the observed 23% reduction in the exacerbation rate is above the minimum clinically important difference.",also observed  reduction exacerbation rate minimum clinically important difference,Positive
243,"Study TRIPLE 6, CHF 5993 had a statistically significant superior effect on moderate and severe COPD exacerbation rate over 52 weeks than Tiotropium.",study triple  chf  statistically significant superior effect moderate severe copd exacerbation rate  weeks tiotropium,Positive
244,The observed 20% reduction in the exacerbation rate is above the minimum clinically important difference.,observed  reduction exacerbation rate minimum clinically important difference,Positive
245,Superiority of CHF 5993 pMDI over Tiotropium and non-inferiority relative to Foster pMDI + Tiotropium in terms pre-dose morning FEV1 at Week 52 was also demonstrated.,superiority chf  pmdi tiotropium noninferiority relative foster pmdi tiotropium terms predose morning fev week  demonstrated,Positive
246,"The superior clinical efficacy of CHF 5993 pMDI compared to Tiotropium was further supported by consistent findings on other relevant parameters, including SGRQ and use of rescue medication.",superior clinical efficacy chf  pmdi compared tiotropium supported consistent findings relevant parameters including sgrq use rescue medication,Positive
248,"Overall, CHF 5993 pMDI has shown benefits in reduction in exacerbation frequency and in improvement in lung function in two large Phase III studies.",overall chf  pmdi shown benefits reduction exacerbation frequency improvement lung function two large phase iii studies,Positive
249,From the safety data presented there are no particular safety signals that suggest an additive effect when FF and GB are administered together.,safety data presented particular safety signals suggest additive effect ff gb administered together,Positive
251,The clinical database is acceptable and considered sufficient.,clinical database acceptable considered sufficient,Positive
252,The clinical safety sections of the SmPC contain appropriate information for each substance and reflect the safety information on the FDC.,clinical safety sections smpc contain appropriate information substance reflect safety information fdc,Positive
253,"In this informed consent application, there are no new issues related to the clinical data. ",informed consent application new issues related clinical data,Positive
254,All the clinical data have been assessed for Nuwiq application and adequately reflected in the Product Information.,clinical data assessed nuwiq application adequately reflected product information,Positive
255,SOF/VEL/VOX for 12 weeks has shown excellent efficacy in patients that have previously failed a regimen containing an NS5A inhibitor.,sofvelvox  weeks shown excellent efficacy patients previously failed regimen containing nsa inhibitor,Positive
256,A similar 12 week course appears somewhat better than SOF/VEL in patients with previous failure on a DAA-containing regimen without an NS5A inhibitor.,similar  week course appears somewhat better sofvel patients previous failure daacontaining regimen without nsa inhibitor,Positive
257,An 8 week course of SOF/VEL/VOX was similarly efficacious as 12 weeks of SOF/VEL in a difficult to cure DAA-naïve cirrhotic GT3 cohort., week course sofvelvox similarly efficacious  weeks sofvel difficult cure daanave cirrhotic gt cohort,Positive
261,"SOF/VEL/VOX has been studied in a sufficient number of patients, including substantial numbers of patients with compensated cirrhosis.",sofvelvox studied sufficient number patients including substantial numbers patients compensated cirrhosis,Positive
262,"Compared to SOF/VEL and placebo, there were similar rates of AEs overall, with the only notable difference being increased rates of mild (Grade 1) nausea and diarrhoea.",compared sofvel placebo similar rates aes overall notable difference increased rates mild grade  nausea diarrhoea,Positive
264,"No treatment-related SAE was reported and only one subject (0.1%) in the Phase 3 trials discontinued SOF/VEL/VOX due to reported advents, assessed unrelated to study drug.",treatmentrelated sae reported one subject  phase  trials discontinued sofvelvox due reported advents assessed unrelated study drug,Positive
266,The safety profile of SOF/VEL/VOX for 8 or 12 weeks in patients with compensated liver disease due to HCV infection appears favourable.,safety profile sofvelvox   weeks patients compensated liver disease due hcv infection appears favourable,Positive
8,This means that further evidence on this medicinal product is awaited,means evidence medicinal product awaited,Negative
10,The CHMP considers the following measures necessary to address the missing efficacy data for 1st line treatment in the context of a conditional MA:,chmp considers following measures necessary address missing efficacy data st line treatment context conditional ma,Negative
14,• PASS: German real-world cohort study should be submitted as additional PhV activity to address the missing information of safety and efficacy in immune compromised patients,pass german realworld cohort study submitted additional phv activity address missing information safety efficacy immune compromised patients,Negative
19,The CHMP considers the following measures necessary to address issues related to safety: ,chmp considers following measures necessary address issues related safety,Negative
29,"Although dataset of AFL patients has been updated, data are still considered very limited to reach firm conclusion about safety proflie.",although dataset afl patients updated data still considered limited reach firm conclusion safety proflie,Negative
30,Additional safety data from maintenance study period CT-P10 3.3 and follow-up period should be provided (see RMP).,additional safety data maintenance study period ctp  followup period provided see rmp,Negative
39,"As questions still remain on the long term safety, ongoing open-label extension studies are being undertaken that will provide further data.",questions still remain long term safety ongoing openlabel extension studies undertaken will provide data,Negative
41,"Only 3 pivotal randomized double-blind multicentre placebo controlled studies (Parsons and Mulholland 1987, Mulholland et al 1990 and Parsons et al 1993) among the 6 pivotal studies met their primary endpoint “GRA” and some secondary endpoints such as pain.", pivotal randomized doubleblind multicentre placebo controlled studies parsons mulholland  mulholland et al  parsons et al  among  pivotal studies met primary endpoint gra secondary endpoints pain,Negative
47,"Due to the heparin-like structure of PPS, a weak anticoagulant effect was observed with PPS and patients with risk factors for increased bleeding (undergoing invasive procedures, having underlying coagulopathy or taking anticoagulants) should be carefully evaluated for haemorrhage during the treatment.",due heparinlike structure pps weak anticoagulant effect observed pps patients risk factors increased bleeding undergoing invasive procedures underlying coagulopathy taking anticoagulants carefully evaluated haemorrhage treatment,Negative
58,"More detailed data on injection site reactions, hypersensitivity and anaphylactic reactions were requested in order to allow a thorough assessment of this issue both in subjects with and without ADAs.",detailed data injection site reactions hypersensitivity anaphylactic reactions requested order allow thorough assessment issue subjects without adas,Negative
71,"With regard to immunogenicity, the differences in the AIA response between SARS342434 and Humalog were small and inconsistent.",regard immunogenicity differences aia response sars humalog small inconsistent,Negative
97,"However, precaution is warranted given a small size of safety database, a limited information on long-term toxicity, and a limited data on PK/PD interactions together with indication on potential for worsening toxicity for VEGFRi -mTOR inhibitor combinations in general.",however precaution warranted given small size safety database limited information longterm toxicity limited data pkpd interactions together indication potential worsening toxicity vegfri mtor inhibitor combinations general,Negative
98,"Although toxicity appears to be manageable with the intended combination, an onset of more frequent or severe toxicity may occur in a larger database and/or at longer term.",although toxicity appears manageable intended combination onset frequent severe toxicity may occur larger database andor longer term,Negative
99,Poor tolerability of the combination is manifest with high rates of discontinuations due to AEs and dose modifications.,poor tolerability combination manifest high rates discontinuations due aes dose modifications,Negative
100,"Therefore, further studies need to be conducted in relevant clinical setting in order to provide comprehensive data and to improve tolerability profile of the combination in view of a limited safety database for the combination treatment at intended doses/schedule, related uncertainties and poor tolerability of the combination (high rate of treatment discontinuation and dose modifications).",therefore studies need conducted relevant clinical setting order provide comprehensive data improve tolerability profile combination view limited safety database combination treatment intended dosesschedule related uncertainties poor tolerability combination high rate treatment discontinuation dose modifications,Negative
102,Study 307 is requested to further characterise the safety and tolerability profile of the combination therapy and further contribute to knowledge on PK and PK/PD of lenvatinib and everolimus and their PK and PD interactions.,study  requested characterise safety tolerability profile combination therapy contribute knowledge pk pkpd lenvatinib everolimus pk pd interactions,Negative
105,Studies requested for Lenvima will also provide relevant safety information for this application,studies requested lenvima will provide relevant safety information application,Negative
112,"Based on these data and since relapses in both SPMS and RRMS patients have the same underlying inflammatory pathophysiology, patients with RMS (instead of RRMS) were considered a more suitable target population.",based data relapses spms rrms patients underlying inflammatory pathophysiology patients rms instead rrms considered suitable target population,Negative
124,"Nevertheless, CHMP noted that since the clinical development has been built mainly to promote the use of this dual therapy in first line treatment rather than in retreatment, the limited sample sized MAGELLAN-1 study (without GT3 patients) in DAA TE leaves many uncertainties for the use of this dual therapy in patients failing DAA.",nevertheless chmp noted clinical development built mainly promote use dual therapy first line treatment rather retreatment limited sample sized magellan study without gt patients daa te leaves many uncertainties use dual therapy patients failing daa,Negative
146,Additional safety data from Maintenance Study Period CT-P10 3.3.and Follow-up Period should be provided (see RMP).,additional safety data maintenance study period ctp and followup period provided see rmp,Negative
171,"ACR20 results per visit showed significant differences which may be interpreted as indicating a faster onset of effect for ABP 501, which could question similarity.",acr results per visit showed significant differences may interpreted indicating faster onset effect abp  question similarity,Negative
185,"The current studies do not provide evidence that the treatment effects persist with indefinite length of treatment, neither in infantile nor in later onset SMA",current studies provide evidence treatment effects persist indefinite length treatment neither infantile later onset sma,Negative
186,The CHMP considers the following measures as key to the B/R ratio of the product and necessary to address issues related to efficacy:,chmp considers following measures key br ratio product necessary address issues related efficacy,Negative
187,"PAES: In order to evaluate the long term efficacy and safety of Nusinersen in symptomatic patients with spinal muscular atrophy, Phase 3, open-label extension study (SHINE, CS11)",paes order evaluate long term efficacy safety nusinersen symptomatic patients spinal muscular atrophy phase  openlabel extension study shine cs,Negative
188,the MAH should conduct and submit the results of the ,mah conduct submit results,Negative
189,"• PAES: In order to evaluate the long term efficacy and safety of Nusinersen in pre-symptomatic patients with spinal muscular atrophy, the MAH should conduct and submit the results of the Phase 2, open-label study (NURTURE (SM201))",paes order evaluate long term efficacy safety nusinersen presymptomatic patients spinal muscular atrophy mah conduct submit results phase  openlabel study nurture sm,Negative
207,The FRC is provided in two different pens with two different ratios between insulin glargine and lixisenatide which may increase the risk for medication errors.,frc provided two different pens two different ratios insulin glargine lixisenatide may increase risk medication errors,Negative
217,There is a lack of long-term data beyond 30 weeks with the FRC. ,lack longterm data beyond  weeks frc,Negative
258,"Further, an 8 week course of SOF/VEL/VOX showed an SVR rate of 95% in a DAA-naïve population; however, this did not meet predefined non-inferiority with SOF/VEL for 12 weeks.",further  week course sofvelvox showed svr rate  daanave population however meet predefined noninferiority sofvel  weeks,Negative
265,"There was no general indication of VOX-associated transaminitis, as has been seen with other NS3/4A inhibitors; however, two cases associated with concomitant ethinyl estradiol among a total of 29 objects exposed, which makes co-administration quite questionable.",general indication voxassociated transaminitis seen nsa inhibitors however two cases associated concomitant ethinyl estradiol among total  objects exposed makes coadministration quite questionable,Negative
3,The median OS time in the updated results exceeded 1 year,median os time updated results exceeded  year,Neutral
7,This medicinal product has been authorised under a so-called ‘conditional approval’ scheme,medicinal product authorised socalled conditional approval scheme,Neutral
9,The European Medicines Agency will review new information on this medicinal product at least every year and this SmPC will be updated as necessary,european medicines agency will review new information medicinal product least every year smpc will updated necessary,Neutral
11,"In order to confirm the efficacy for chemotherapy-naïve treated patients, the MAH should submit the final results of study EMR 100070-003 – Part B",order confirm efficacy chemotherapynave treated patients mah submit final results study emr  part b,Neutral
12,The final results of the study should be submitted by 30th January 2020,final results study submitted th january ,Neutral
13,The CHMP considers that additional supportive data on efficacy will be provided also from the following post-authorisation safety study: ,chmp considers additional supportive data efficacy will provided following postauthorisation safety study,Neutral
18,The safety risks associated with immune related adverse reactions are managed through additional risk minimisation activities implemented in the form of educational materials that will inform HCPs and patients on how to identify and properly handle suspected immune related ADRs,safety risks associated immune related adverse reactions managed additional risk minimisation activities implemented form educational materials will inform hcps patients identify properly handle suspected immune related adrs,Neutral
25,The overall safety profile of CT-P10 appeared roughly similar to that of the reference product although the pooled incidences of AEs and SAEs were generally lower for the reference products.,overall safety profile ctp appeared roughly similar reference product although pooled incidences aes saes generally lower reference products,Neutral
27,"Most common reported events were infections, infusion related reactions.",common reported events infections infusion related reactions,Neutral
31,The planned extension studies CT-P10 3.2 (RA) CT-P10 3.3 (AFL) and CT-P10 3.4 (LTBFL) listed in the RMP will provide additional long term safety data.,planned extension studies ctp  ra ctp  afl ctp  ltbfl listed rmp will provide additional long term safety data,Neutral
35,No significant additional benefit was observed with weekly dosing versus Q2W dosing (300 mg s.c) in the overall population.,significant additional benefit observed weekly dosing versus qw dosing  mg sc overall population,Neutral
36,"Therefore, the CHMP endorsed the proposed dose of 300 mg every other week (Q2W) with a loading dose of 600 mg on day 1.",therefore chmp endorsed proposed dose  mg every week qw loading dose  mg day ,Neutral
38,"With regard to TEAE profile, no meaningful qualitative and quantitative differences were seen as to short-term and long-term treatment as well as to the dose regimen.",regard teae profile meaningful qualitative quantitative differences seen shortterm longterm treatment well dose regimen,Neutral
40,The applicant provided six pivotal studies to support this application.,applicant provided six pivotal studies support application,Neutral
42,"Based on the primary meta-analysis conducted by the applicant including the six pivotal studies, the estimated benefit differences reached about 13% (ITT and as reported).",based primary metaanalysis conducted applicant including six pivotal studies estimated benefit differences reached  itt reported,Neutral
43,This benefit difference (PPS versus placebo) reached 17% when excluding 2 pivotal studies (Holm-Bentzen et al 1987 and Nickel et al 2015) with the lowest response rates and with a population less homogeneous than in the four other clinical studies (mixing both broad IC/BPS),benefit difference pps versus placebo reached  excluding  pivotal studies holmbentzen et al  nickel et al  lowest response rates population less homogeneous four clinical studies mixing broad icbps,Neutral
44,"Indeed, this benefit difference was mainly driven by the statistically significant results of the three pivotal studies Parsons et al 1993, Mulholland et al 1990 and Parsons and Mulholland 1987 including patients falling within ESSIC classification 2X to 3C.",indeed benefit difference mainly driven statistically significant results three pivotal studies parsons et al  mulholland et al  parsons mulholland  including patients falling within essic classification x c,Neutral
62,There was no clinical efficacy study performed to support the biosimilarity claim.,clinical efficacy study performed support biosimilarity claim,Neutral
64,"For the purpose of the clinical biosimilarity exercise for biosimilar insulin products, the evaluation of HbA1c is not a sensitive endpoint and therefore efficacy studies evaluating HbA1c are not requested (EMEA/CHMP/BMWP/32775/2005_Rev.",purpose clinical biosimilarity exercise biosimilar insulin products evaluation hbac sensitive endpoint efficacy studies evaluating hbac requested emeachmpbmwprev,Neutral
65,"1).Nevertheless, the applicant has conducted two large efficacy and safety (phase III) non-inferiority studies comparing the test and reference products in order to investigate how PK/PD features of the biosimilar candidate product translate into clinical parameters relevant for the management of patients with Type 1 and 2 DM.",nevertheless applicant conducted two large efficacy safety phase iii noninferiority studies comparing test reference products order investigate pkpd features biosimilar candidate product translate clinical parameters relevant management patients type   dm,Neutral
85,The safety observation is based on a total of 3354 patients exposed to at least 1 dose of sarilumab for a total of 5981.0 patient-years of exposure.,safety observation based total  patients exposed least  dose sarilumab total  patientyears exposure,Neutral
86,"Sarilumab is associated with infections (including serious infections), decrease in ANC and platelet count, and increase in ALT and lipids, all of which are events consistent with the known effect of IL-6 inhibition, and with injection site reactions, consistent with a SC route of administration.",sarilumab associated infections including serious infections decrease anc platelet count increase alt lipids events consistent known effect il inhibition injection site reactions consistent sc route administration,Neutral
103,Study 221 will continue to characterize safety for the combination treatment in patients with non clear cell renal carcinoma.,study  will continue characterize safety combination treatment patients non clear cell renal carcinoma,Neutral
104,"Study 010 will assess in vitro lenvatinib protein binding, determine the unbound drug concentrations in order to define correctly the dose-adjustment in patients with severe hepatic and renal impairment.",study  will assess vitro lenvatinib protein binding determine unbound drug concentrations order define correctly doseadjustment patients severe hepatic renal impairment,Neutral
110,Subgroup analyses suggested a larger effect size in patients with high disease activity.,subgroup analyses suggested larger effect size patients high disease activity,Neutral
115,No clinically relevant added benefit of additional treatment cycles beyond year 2 was evident.,clinically relevant added benefit additional treatment cycles beyond year  evident,Neutral
117,"The main safety issues were related to the risks of prolonged severe lymphopenia, infections including reactivation of latent infections and opportunistic infections as well as malignancies.",main safety issues related risks prolonged severe lymphopenia infections including reactivation latent infections opportunistic infections well malignancies,Neutral
118,"For the latter, uncertainties due to the observed imbalance of cases occurring in patients treated with cladribine compared to placebo as well as the low number of events remained, although supportive analyses did not support a causal association.",latter uncertainties due observed imbalance cases occurring patients treated cladribine compared placebo well low number events remained although supportive analyses support causal association,Neutral
120,Of particular interest this FDC comprises two pangenotypic components with high potency and high genetic barrier.,particular interest fdc comprises two pangenotypic components high potency high genetic barrier,Neutral
122,"As part of the response to CHMP questions throughout the assessment, some clarifications and some additional data from ongoing studies (EXPEDITION-2 notably) were provided by the applicant in support of the efficacy of the product.",part response chmp questions throughout assessment clarifications additional data ongoing studies expedition notably provided applicant support efficacy product,Neutral
126,"While the risk of ALT elevations seems lower as compared to previously authorized NS3/4A, it remains that some situations (namely in case of combination with EE-based regimens) have been identified at increased hepatic risk.",risk alt elevations seems lower compared previously authorized nsa remains situations namely case combination eebased regimens identified increased hepatic risk,Neutral
128,"To support the application, the applicant has submitted one bioequivalence study.",support application applicant submitted one bioequivalence study,Neutral
129,"It was a randomized, blind, 1-way parallel bioequivalence study of nitisinone 10 mg capsule and Orfadin (reference) following a 10 mg dose in healthy subjects under fasting conditions.",randomized blind way parallel bioequivalence study nitisinone  mg capsule orfadin reference following  mg dose healthy subjects fasting conditions,Neutral
131,No additional clinical studies were provided within current application.,additional clinical studies provided within current application,Neutral
132,A clinical overview has been provided and was based on up-to-date and adequate scientific literature.,clinical overview provided based uptodate adequate scientific literature,Neutral
174,The secondary endpoints PASI 75 and sPGA showed point estimates of 7% difference with a wide CI.,secondary endpoints pasi  spga showed point estimates  difference wide ci,Neutral
180,"The difference in magnitude across endpoints is in alignment with the understanding of the pathology of SMA, where deficiency in SMN protein leads to disease progression from events more proximal to the action of SMN such as declines in motor neuron health as measured by CMAP and CHOP INTEND, through those that are more distal, as measured by motor milestones and event-free survival",difference magnitude across endpoints alignment understanding pathology sma deficiency smn protein leads disease progression events proximal action smn declines motor neuron health measured cmap chop intend distal measured motor milestones eventfree survival,Neutral
190,"Along with the needed data on efficacy and safety to be derived from the above studies, their protocols include PK data collections",along needed data efficacy safety derived studies protocols include pk data collections,Neutral
191,"These are being used to collect the required PK data in order to enable the company to make future decisions about whether any dose adjustment, or further investigation in to dose adjustment, is required",used collect required pk data order enable company make future decisions whether dose adjustment investigation dose adjustment required,Neutral
192,CSF data are being collected from both these studies and will be used in the comprehensive update to the Pop PK model,csf data collected studies will used comprehensive update pop pk model,Neutral
193,"Additionally, the following measures will contribute to the better understanding of the efficacy, safety and clinical applicability of the product: ",additionally following measures will contribute better understanding efficacy safety clinical applicability product,Neutral
194,"• EMBRACE (SM202) - Phase 2, randomized, double-blind, sham- procedure controlled study to assess the safety, tolerability, PK, and efficacy in patients who were not eligible to participate in studies CS3b or CS4 ",embrace sm phase  randomized doubleblind sham procedure controlled study assess safety tolerability pk efficacy patients eligible participate studies csb cs,Neutral
195,• Registries initiative - Collaborations with existing disease registries across the globe to capitalize on the available clinical experts and networks and modifying to be able to collect appropriate information and take in to account availability of medicinal product(s),registries initiative collaborations existing disease registries across globe capitalize available clinical experts networks modifying able collect appropriate information take account availability medicinal products,Neutral
196,• Exploring higher doses - The company is requested to explore whether higher doses of nusinersen could show greater efficacy,exploring higher doses company requested explore whether higher doses nusinersen show greater efficacy,Neutral
197,"The safety profile of nusinersen was characterized in subjects with infantile-onset SMA in a randomized controlled study and an open-label study; pre-symptomatic infants with SMA in an open-label study, and children with later-onset SMA in a randomized study and open-label studies",safety profile nusinersen characterized subjects infantileonset sma randomized controlled study openlabel study presymptomatic infants sma openlabel study children lateronset sma randomized study openlabel studies,Neutral
200,"Pre-symptomatic infants treated with nusinersen experienced fewer adverse events compared with symptomatic infants which is most likely due to their healthier baseline condition, which they maintained throughout participation in the study",presymptomatic infants treated nusinersen experienced fewer adverse events compared symptomatic infants likely due healthier baseline condition maintained throughout participation study,Neutral
205,Long-term safety data will be obtained from the planned and ongoing studies.,longterm safety data will obtained planned ongoing studies,Neutral
209,Insulin glargine primarily reduces HbA1c by decreasing the fasting plasma glucose whereas lixisenatide primarily reduces the post-prandial glucose excursion.,insulin glargine primarily reduces hbac decreasing fasting plasma glucose whereas lixisenatide primarily reduces postprandial glucose excursion,Neutral
210,"The major contribution in HbA1c is due to insulin glargine as the treatment difference between the FRC and insulin glargine ranged from 0.3 % to 0.5 %, whereas the treatment difference between the FRC and lixisenatide was 0.8 %.",major contribution hbac due insulin glargine treatment difference frc insulin glargine ranged   whereas treatment difference frc lixisenatide ,Neutral
212,"There was no difference in insulin dose with the FRC compared to monotherapy with insulin glargine in any of the studies, thus there was no insulin “saving” effect with the FRC when the insulin dose in the comparator group was capped at 60 U. ",difference insulin dose frc compared monotherapy insulin glargine studies thus insulin saving effect frc insulin dose comparator group capped  u,Neutral
213,The effect was consistent across studies and across investigated subgroups.,effect consistent across studies across investigated subgroups,Neutral
214,"In the studies, the FRC was always to be taken before breakfast, whereas the proposed SmPC states that Suliqua can be taken prior to any meal.",studies frc always taken breakfast whereas proposed smpc states suliqua taken prior meal,Neutral
215,It is acknowledged that both insulin glargine and lixisenatide may be taken at any time of the day when used in mono-therapy.,acknowledged insulin glargine lixisenatide may taken time day used monotherapy,Neutral
216,"The recommendation has been further supported by data from the lixisenatide file, showing that no statistically significant differences are observed between pre-breakfast or pre-dinner dosing of lixisenatide.",recommendation supported data lixisenatide file showing statistically significant differences observed prebreakfast predinner dosing lixisenatide,Neutral
222,The adverse reaction patterns differed however in the aspect that the FRC group had a lower frequency of subjects with gastrointestinal adverse reactions compared to the lixisenatide group but a higher frequency of subjects with these reactions compared to use with insulin glargine.,adverse reaction patterns differed aspect frc group lower frequency subjects gastrointestinal adverse reactions compared lixisenatide group higher frequency subjects reactions compared use insulin glargine,Neutral
224,"However, it should be noted that concomitant use of SU was not allowed in the present studies with FRC.",however noted concomitant use su allowed present studies frc,Neutral
230,"The separate components of the D/C/F/TAF fixed dose combination are already approved, also for use with specific combination.",separate components dcftaf fixed dose combination already approved use specific combination,Neutral
232,"A non-inferior efficacy of D/C/F/TAF vs DRV+COBI+TVD has been shown in the phase 2 study, although a higher than expected discontinuation rate was observed in the D/C/F/TAF group.",noninferior efficacy dcftaf vs drvcobitvd shown phase  study although higher expected discontinuation rate observed dcftaf group,Neutral
240,"TDI focal score, the third co-primary endpoint, had a clinically relevant improvement with both treatments, but the mean difference between treatments in TDI focal score at week 26 was not statistically significant.",tdi focal score third coprimary endpoint clinically relevant improvement treatments mean difference treatments tdi focal score week  statistically significant,Neutral
247,"For these parameters, CHF 5993 pMDI and Foster pMDI + Tiotropium generally showed a similar effect.",parameters chf  pmdi foster pmdi tiotropium generally showed similar effect,Neutral
250,"The main side effects that have been observed with CHF 5993 are associated with the known ICS, LAMA and LABA effects.",main side effects observed chf  associated known ics lama laba effects,Neutral
259,The addition of VOX appears to increase the barrier to resistance compared to SOF/VEL alone.,addition vox appears increase barrier resistance compared sofvel alone,Neutral
260,Conclusions concerning recommended use are discussed in the B/R section.,conclusions concerning recommended use discussed br section,Neutral
263,"Other potentially related AE’s including decreased appetite, vomiting, muscle spasms and rash.",potentially related aes including decreased appetite vomiting muscle spasms rash,Neutral
